SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila gets regulatory approval of Lipaglyna in Mexico

10 Nov 2017 Evaluate

Zydus Cadila has received an approval from Mexico regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) to market Lipaglyn (Saroglitazar Magnesium) in Mexico for the treatment of Dyslipidemia in patients with diabetes mellitus type 2 and Hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins.

Elevated triglycerides and insulin resistance are two key components of the metabolic syndrome, which medical science believes are responsible for diseases like hypertriglyccridemia, diabetic dyslipidemia or Non-Alcoholic Steatohepatitis disease (NASH).

Increased triglyceride accumulation in the liver can also lead to inflammation, fibrosis, cirrhosis and liver failure, a serious medical condition known as NAFLD or NASH. Additionally, the company is currently evaluating Saroglitazar in several clinical trials for treating liver conditions like NASH and Primary Biliary Cholangitis (PBC).

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.


Zydus Lifesciences Share Price

946.80 7.90 (0.84%)
11-May-2026 12:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1878.25
Dr. Reddys Lab 1289.50
Cipla 1329.10
Zydus Lifesciences 946.80
Lupin 2262.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×